People: Endocyte Inc (ECYT.OQ)
ECYT.OQ on NASDAQ Stock Exchange Global Select Market
18.80USD
1 Aug 2013
18.80USD
1 Aug 2013
Price Change (% chg)
$0.83 (+4.62%)
$0.83 (+4.62%)
Prev Close
$17.97
$17.97
Open
$18.12
$18.12
Day's High
$18.86
$18.86
Day's Low
$18.03
$18.03
Volume
94,419
94,419
Avg. Vol
77,789
77,789
52-wk High
$18.86
$18.86
52-wk Low
$7.50
$7.50
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Aplin |
66 | 2011 | Independent Chairman of the Board |
P. Ron Ellis |
51 | 1996 | President, Chief Executive Officer, Director |
Michael Sherman |
49 | 2006 | Chief Financial Officer |
Philip Low |
65 | 1998 | Chief Science Officer, Director |
Scot Harper |
2013 | Vice President - Clinical Operations | |
Christopher Leamon |
46 | 2000 | Vice President - Research |
Chandra Lovejoy |
41 | 2010 | Vice President - Regulatory Affairs |
Binh Nguyen |
54 | 2011 | Vice President - Clinical Affairs |
Allen Ritter |
51 | 2005 | Vice President - Manufacturing and Chemistry Manufacturing Control |
Beth Taylor |
47 | 2011 | Corporate Controller |
David Meek |
49 | 2012 | Chief Commercial Officer |
Marc Kozin |
51 | 2012 | Director |
Peter Meldrum |
65 | 2012 | Director |
Lesley Russell Cooper |
52 | 2013 | Director |
Keith Brauer |
63 | 2006 | Independent Director |
Ann Hanham |
61 | 2004 | Independent Director |
Fred Middleton |
63 | 2001 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Aplin |
Dr. John C. Aplin, Ph.D., is Independent Chairman of the Board of Endocyte, Inc. since May 2011. Dr. Aplin has served as a member of the Board of Directors since May 2003. Since November 1990, Dr. Aplin has served as General Partner and Managing Director of CID Capital, a venture capital firm. Dr. Aplin has served on the board of directors of 25 companies and was the Chairperson of the M.B.A. program at Indiana University. Dr. Aplin holds a B.S. in business administration from Drake University, and an M.A. in industrial and labor relations and a Ph.D. in business administration from the University of Iowa. Dr. Aplin is also a Certified Management Consultant. |
P. Ron Ellis |
Mr. P. Ron Ellis is President, Chief Executive Officer, Director of Endocyte, Inc. From May 1987 to December 1995, Mr. Ellis served in various positions at Hill-Rom Company, but most recently as Vice President of Strategy and Corporate Development of the specialty care division. Mr. Ellis holds a B.S. in computer science and an M.B.A. from Brigham Young University and a certification in regulatory affairs from Purdue University. |
Michael Sherman |
Mr. Michael A. Sherman is Chief Financial Officer of Endocyte, Inc. From December 1994 to October 2006, Mr. Sherman served in executive roles, but most recently as Vice President of Finance and Strategic Planning from May 2004 to October 2006, of Guidant Corporation, or Guidant, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Sherman holds a B.A. in economics from DePauw University and an M.B.A. from the Amos Tuck School, Dartmouth College. |
Philip Low |
Dr. Philip S. Low, Ph.D., is Chief Science Officer, Director of Endocyte, Inc. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low holds a B.S. in chemistry from Brigham Young University and a Ph.D. in biochemistry from the University of California, San Diego. |
Scot Harper |
Dr. Scot L. Harper, Ph.D., is Vice President - Clinical Operations of Endocyte Inc. Dr. Harper brings more than twenty-five years of clinical operations experience to his position at Endocyte. He joins the company from PAREXEL International, where he was the global portfolio director for oncology, overseeing clinical activities for oncology drugs ranging from Phase 1 to Phase 4 of development. Prior to this position, he was the vice president of Novartis’ North American clinical operations, where he managed clinical operations of all stages of development, including products such as Gleevec, Tasigna and Diovan. Before this, he was at Eli Lilly and Company, where he held a variety of senior roles, most recently senior director of clinical operations, which included oversight of clinical trials in areas including oncology, neuroscience, diabetes and men’s health. Dr. Harper began his career at SmithKline Beecham, where he worked in new product development. Dr. Harper holds a doctorate in cardiovascular physiology from Indiana University School of Medicine, a master’s degree in physiology from Indiana University School of Medicine, a master’s degree in business from the University of South Alabama and a bachelor’s degree in zoology from DePauw University |
Christopher Leamon |
Dr. Christopher P. Leamon, Ph.D., is Vice President - Research of Endocyte, Inc. From February 1999 to April 2000, Dr. Leamon served as the Director of Biology and Biochemistry. Prior to that, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome and DNA drug delivery for GlaxoWellcome, a healthcare company, in December 2000, and Isis Pharmaceuticals, a biomedical pharmaceutical company. Dr. Leamon holds a B.S. in chemistry from Baldwin Wallace College and a Ph.D. in biochemistry from Purdue University. |
Chandra Lovejoy |
Ms. Chandra D. Lovejoy is Vice President - Regulatory Affairs of Endocyte, Inc. From December 2007 to May 2010, Ms. Lovejoy served as the Director of Regulatory Affairs. Ms. Lovejoy served in positions at Genentech, a biotechnology company and an indirectly wholly owned subsidiary of From December 2007 to May 2010, Ms. Lovejoy served as the Director of Regulatory Affairs. Ms. Lovejoy served in positions at Genentech, a biotechnology company and an indirectly wholly owned subsidiary of Roche Holdings, a healthcare company, including Manager of Regulatory Affairs. Ms. Lovejoy holds an M.S. in regulatory affairs from San Diego State University and a B.S. in organizational behavior from the University of San Francisco. |
Binh Nguyen |
Dr. Binh Nguyen, M.D., Ph.D. is Vice President - Clinical Affairs of Endocyte Inc. From August 2005 to June 2011, he served as Chief Medical Officer at Tigris Pharmaceuticals, Inc. and prior to August 2005, he worked at Eli Lilly & Company for 10 years, most recently as Executive Director, Global Oncology Platform Team, for which he was responsible for the global development of Gemzar®, Alimta®, and Enzastaurin. Dr. Nguyen received his Ph.D. in organic chemistry from Georgetown University and his M.D. from the University of Maryland. He completed fellowships at the National Cancer Institute and worked at the FDA’s Division of Oncology as a medical reviewer. |
Allen Ritter |
Dr. Allen R. Ritter, Ph.D., is Vice President - Manufacturing and Chemistry Manufacturing Control of Endocyte, Inc. From May 2004 to December 2005, Dr. Ritter served as the Director of Development, CMC and Manufacturing. Dr. Ritter holds a B.S. in chemistry from St. Olaf College, an M.S. in organic chemistry from the University of Pittsburgh, and a Ph.D. in synthetic organic chemistry from the University of Notre Dame. |
Beth Taylor |
Ms. Beth A. Taylor is Corporate Controller of Endocyte, Inc. She served as Corporate Controller of Author Solutions, Inc. from December 2009 to December 2010, as Vice President of Accounting, Financial Reporting and Control at Harlan Laboratories, Inc. from July 2007 to May 2009 and in various roles at Republic Airways Holdings, Inc. from May 1999 through June 2007, including Vice President and Corporate Controller from August 2004 through June 2007. Ms. Taylor holds a B.S. in Accounting from Indiana University. |
David Meek |
Mr. David D. Meek is Chief Commercial Officer of Endocyte Inc. He was head of oncology at Novartis Oncology for northern and central Europe from January 2010 to August 2012. From July 2007 to December 2009, he was president and CEO of Novartis Canada. Prior to joining Novartis, Mr. Meek held a variety of executive sales and marketing roles at Johnson & Johnson. Mr. Meek holds a B.A. in management from the University of Cincinnati. |
Marc Kozin |
Mr. Marc Kozin has been appointed as Director of Endocyte, Inc., effective July 25, 2012. Mr. Kozin is currently a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm. Having served as president of L.E.K.'s North American practice for 15 years, Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also has deep industry advising biopharmaceutical, life sciences, and medical technology companies. Mr. Kozin received his B.A. with distinction, in Economics from Duke University. He was also awarded an M.B.A. with distinction from The Wharton School, University of Pennsylvania. |
Peter Meldrum |
Dr. Peter D. Meldrum has been appointed as Director of Endocyte, Inc., effective July 9, 2012. He has held his current position since 1992. Prior to his time at Myriad, he was president and chief executive officer of Founders Fund, Inc. He is active in the community and is a member of the Board of Trustees of Westminster College, Ballet West and Pioneer Theatre Company. Mr. Meldrum received a Doctorate of Engineering degree (honorary) from the University of Utah in 2009, a Doctorate of Science degree (honorary) from Westminster College in 2004, an MBA degree from the University of Utah in 1974 and a B.S. degree in Chemical Engineering from the University of Utah in 1970. |
Lesley Russell Cooper |
Dr. Lesley Russell Cooper, M.B.Ch.B., has been appointed as Director of Endocyte, Inc., effective January 8, 2013. Dr. Russell served as senior vice president and head of research and development for global branded products at Teva Pharmaceuticals until June 2012. Prior to this position she was executive vice president and chief medical officer at Cephalon. Dr. Russell joined Cephalon in 2000 and held various positions of increasing responsibility, including head of clinical research and medical affairs, prior to becoming Cephalon’s chief medical officer in September 2006. During her tenure at Cephalon, Dr. Russell filed multiple new drug applications (NDAs) to the FDA and marketing authorization applications (MAAs) to the Committee for Medicinal Products for Human Use (CHMP). Before joining Cephalon, Dr. Russell held positions of increasing responsibility at Amgen U.K., Lilly Industries, U.K., and U.S. Bioscience, now acquired by MedImmune Oncology. Before joining the pharmaceutical industry, Dr. Russell was trained in hematology and oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children in Edinburgh, Scotland, and was a research fellow at University of Edinburgh. Dr. Russell received a M.B.Ch.B. degree from the University of Edinburgh, Scotland. She is a member of the Royal College of Physicians, U.K., and is registered with the General Medical Council, U.K. She currently serves as a member of the board of directors of AMAG Pharma, a company traded on NASDAQ. |
Keith Brauer |
Mr. Keith E. Brauer is Independent Director of Endocyte, Inc., since August 2006. From August 1999 through December 2011, Mr. Brauer served in various roles at the Community Hospitals of Indianapolis, or CHI, including roles with CHI’s affiliate, Indiana Heart Hospital, or IHH. Mr. Brauer served as a member of CHI’s finance committee from August 1999 to December 2011, and as a member of IHH’s board of directors from April 2006 to December 2011, as Chairman of IHH’s board of directors. Mr. Brauer was also a member of CHI’s board of directors from October 2000 to December 2009 and as Chairman of CHI’s board of directors from August 2003 to August 2005. He has also served on the board of directors since June 2006 and chairman of the audit committee since September 2006 of NanoInk, Inc., a nanometer-scale manufacturing and applications development company. He has also served on the board of directors since August 2008 and chairman of the audit committee since October 2008 of NICO Corporation, a neurosurgery company. From 1988 to 1994, Mr. Brauer served in various executive roles at Eli Lilly and Company, a healthcare company, most recently as Executive Director and Chief Accounting Officer. From July 1994 to April 2006, Mr. Brauer served as Vice President, Finance and Chief Financial Officer of Guidant, which was acquired by Boston Scientific Corporation, a medical device company, in April 2006. Mr. Brauer retired with full benefits after the acquisition of Guidant and has not sought full time employment since that time. Mr. Brauer occasionally consults for investors in the medical device industry. Mr. Brauer holds a B.S. in management from Indiana University and an M.B.A. from the University of Michigan and has been a member of the Financial Executives Institute since 1984. |
Ann Hanham |
Dr. Ann F. Hanham, Ph.D., is Independent Director of Endocyte, Inc., since November 2004. Dr. Hanham joined Burrill & Company, a venture capital and merchant banking firm, in February 2000 and has served as a Managing Director there since January 2002. Dr. Hanham served on the board of directors of BioMimetic Therapeutics, Inc., a biopharmaceutical company, from May 2001 to September 2006; Biotie Therapies, a drug discovery and development company, from March 2009 to April 2011; and Targacept, a biopharmaceutical company, from September 2005 to August 2006. Dr. Hanham holds a B.Sc. from the University of Toronto, a M.Sc. from Simon Fraser University and a Ph.D. from the University of British Columbia. |
Fred Middleton |
Mr. Fred A. Middleton is Independent Director of Endocyte, Inc., since July 2001. Since 1987, Mr. Middleton has been a General Partner and Managing Director of Sanderling Ventures, a biomedical venture capital firm. During the last 30 years, Mr. Middleton has served in a number of roles as a member of management, board member or an investor of in over 25 biomedical companies. Mr. Middleton currently serves as Chairman of the Board of directors of Stereotaxis (STXS), a medical device company, as Chairman of the Board of Pacira Pharmaceuticals (PCRX), and as a member of board of directors of CardioNet (BEAT), a cardiac rhythm management services company. Mr. Middleton also serves on the board of directors of six other privately-held biomedical and biotechnology companies. He holds a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. with Distinction from the Harvard Business School. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Aplin |
-- |
P. Ron Ellis |
1,648,800 |
Michael Sherman |
740,528 |
Philip Low |
496,005 |
Scot Harper |
-- |
Christopher Leamon |
734,605 |
Chandra Lovejoy |
-- |
Binh Nguyen |
1,031,040 |
Allen Ritter |
226,826 |
Beth Taylor |
-- |
David Meek |
-- |
Marc Kozin |
-- |
Peter Meldrum |
-- |
Lesley Russell Cooper |
-- |
Keith Brauer |
-- |
Ann Hanham |
-- |
Fred Middleton |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
John Aplin |
0 | 0 |
P. Ron Ellis |
22,012 | 28,033 |
Michael Sherman |
20,942 | 22,591 |
Philip Low |
0 | 0 |
Scot Harper |
0 | 0 |
Christopher Leamon |
20,073 | 160,479 |
Chandra Lovejoy |
0 | 0 |
Binh Nguyen |
0 | 0 |
Allen Ritter |
0 | 0 |
Beth Taylor |
0 | 0 |
David Meek |
0 | 0 |
Marc Kozin |
0 | 0 |
Peter Meldrum |
0 | 0 |
Lesley Russell Cooper |
0 | 0 |
Keith Brauer |
0 | 0 |
Ann Hanham |
0 | 0 |
Fred Middleton |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
ELLIS P RON |
3,000 | $1.91 |
ELLIS P RON |
3,000 | $17.01 |
HANHAM ANN F |
1,569 | $14.25 |
HANHAM ANN F |
131 | $14.25 |
HANHAM ANN F |
630 | $14.07 |
HANHAM ANN F |
7,570 | $14.07 |
RITTER ALLEN R |
5,000 | $2.10 |
HANHAM ANN F |
15,141 | $14.39 |
NGUYEN BINH |
2,700 | $3.55 |
HANHAM ANN F |
1,259 | $14.39 |
HANHAM ANN F |
10,155 | $14.31 |
HANHAM ANN F |
845 | $14.31 |
RITTER ALLEN R |
483 | $14.17 |
HANHAM ANN F |
11,633 | $14.42 |
HANHAM ANN F |
967 | $14.42 |
NGUYEN BINH |
17,300 | $14.42 |
HANHAM ANN F |
1,121 | $14.37 |
HANHAM ANN F |
13,479 | $14.37 |
NGUYEN BINH |
17,300 | $3.55 |
HANHAM ANN F |
1,735 | $14.44 |
HANHAM ANN F |
20,865 | $14.44 |
HANHAM ANN F |
18,464 | $14.43 |
HANHAM ANN F |
1,536 | $14.43 |
HANHAM ANN F |
18,649 | $14.94 |
HANHAM ANN F |
1,551 | $14.94 |

